Mabion S.A. (WSE:MAB)
Poland flag Poland · Delayed Price · Currency is PLN
9.64
-0.06 (-0.62%)
Jun 6, 2025, 5:00 PM CET

Mabion Company Description

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.

The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases.

It also offers clinical and commercial drug substance manufacturing of therapeutic proteins using mammalian and insect cell cultures, including biosimilars, monoclonals, vaccine antigens, and other recombinant proteins.

Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is headquartered in Konstantynów Łódzki, Poland.

Mabion S.A.
Country Poland
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 213
CEO Krzysztof Kaczmarczyk

Contact Details

Address:
ul. gen. Mariana Langiewicza 60
Konstantynów Lódzki, 95-050
Poland
Phone 48 42 207 7890
Website mabion.eu

Stock Details

Ticker Symbol MAB
Exchange Warsaw Stock Exchange
Fiscal Year January - December
Reporting Currency PLN
ISIN Number PLMBION00016
SIC Code 2836

Key Executives

Name Position
Krzysztof Kaczmarczyk Chief Executive Officer and President of Management Board
Grzegorz Grabowicz Chief Financial Officer, Financial Director and Member of Management Board
Dr. Slawomir Jaros EMBA, Eng., Ph.D. Member of the Management Board and Scientific and Quality Director
Adam Pietruszkiewicz Member of Management Board and Business Development Director
Julita Balcerek M.D. Member of the Management Board, Operations Director and Chief Operating Officer
Aneta Turek Chief Accountant
Pawel Pobiedzinski Head of Logistics and Procurement
Joanna Krolasik Head of Microbiology Laboratory